Sadaaki Maeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sadaaki Maeda has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Yasuhiro Yoshioka
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka, 573-0101, Japan
9 shared publications Akiko Yamamuro
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan
7 shared publications- Yuki Ishimaru
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan
7 shared publications Fumiya Shibagaki
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan
4 shared publicationsAkihide Sumino
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan
3 shared publications- Akiko Yamamuro
Laboratory of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka, 573-0101, Japan
3 shared publications
Latest Publications
- Open Access
- 20 March 2020
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 12, 58
Endogenous Apelin Is Protective Against Age-Associated Loss of Retinal Ganglion Cells in Mice
Age-associated loss of retinal ganglion cells (RGCs) causes visual deficits, but there is not yet any therapeutic agent to prevent the loss of these cells. Herein, we report that apelin, an endogenous peptide ligand of APJ receptor, is protective against the age-related loss of RGCs in mice. The mRNA expression of apelin was reduced in the retina of old mice compared with that in young mice, whereas retinal APJ expression increased with age. Immunofluorescence staining showed that APJ was present in RGCs and their surrounding cells expressed apelin. In addition, both functional and histological analyses demonstrated that apelin deficiency accelerated the loss of RGCs associated with age in mice. These results suggest that endogenous apelin plays a protective role against the degeneration of RGCs and that the apelinergic axis may be a new target for preventing age-related visual impairment.
- 20 March 2020
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 12, 58
Open AccessEndogenous Apelin Is Protective Against Age-Associated Loss of Retinal Ganglion Cells in Mice
Age-associated loss of retinal ganglion cells (RGCs) causes visual deficits, but there is not yet any therapeutic agent to prevent the loss of these cells. Herein, we report that apelin, an endogenous peptide ligand of APJ receptor, is protective against the age-related loss of RGCs in mice. The mRNA expression of apelin was reduced in the retina of old mice compared with that in young mice, whereas retinal APJ expression increased with age. Immunofluorescence staining showed that APJ was present in RGCs and their surrounding cells expressed apelin. In addition, both functional and histological analyses demonstrated that apelin deficiency accelerated the loss of RGCs associated with age in mice. These results suggest that endogenous apelin plays a protective role against the degeneration of RGCs and that the apelinergic axis may be a new target for preventing age-related visual impairment.
- 1 January 2020
- Published by Springer Nature in Neurochemical Research
- Vol. 45 (4) , 752-759
Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-Induced Loss of Retinal Neuronal Cells in Mice
Glutamate excitotoxicity via N-methyl-d-aspartate (NMDA) receptors is thought to be a factor involved in the loss of retinal neuronal cells, including retinal ganglion cells, in retinal diseases such as diabetic retinopathy and acute angle closure glaucoma. Herein we report the protective effect of systemic administration of ML233, an apelin receptor agonist, against retinal neuronal cell death induced by the intravitreal injection of NMDA into mice. Intraperitoneal administration of ML233 prevented the NMDA-induced reduction in the amplitude of scotopic threshold responses (STR), which mainly reflect the activity of the retinal ganglion cells. Immunohistochemical staining showed that ML233 inhibited the NMDA-induced loss of retinal ganglion cells and amacrine cells. In addition, ML233 suppressed the breakdown of spectrin αII, a neuronal cytoskeleton protein cleaved by calpain activation, in the retina after intravitreal injection of NMDA. Intraperitoneal administration of ML233 increased the phosphorylation of Akt, a potent anti-apoptotic protein in neurons, in the retina. Furthermore, oral administration of ML233 protected against the decrease in the STR amplitudes and the loss of retinal ganglion cells caused by NMDA. These results suggest that systemic administration of ML233 protected retinal neurons from NMDA receptor-mediated excitotoxicity and that drugs activating the apelin receptor may be a new candidate for preventing the progression of these retinal diseases.
- 1 January 2020
- Published by Springer Nature in Neurochemical Research
- Vol. 45 (4) , 752-759
Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-Induced Loss of Retinal Neuronal Cells in Mice
Glutamate excitotoxicity via N-methyl-d-aspartate (NMDA) receptors is thought to be a factor involved in the loss of retinal neuronal cells, including retinal ganglion cells, in retinal diseases such as diabetic retinopathy and acute angle closure glaucoma. Herein we report the protective effect of systemic administration of ML233, an apelin receptor agonist, against retinal neuronal cell death induced by the intravitreal injection of NMDA into mice. Intraperitoneal administration of ML233 prevented the NMDA-induced reduction in the amplitude of scotopic threshold responses (STR), which mainly reflect the activity of the retinal ganglion cells. Immunohistochemical staining showed that ML233 inhibited the NMDA-induced loss of retinal ganglion cells and amacrine cells. In addition, ML233 suppressed the breakdown of spectrin αII, a neuronal cytoskeleton protein cleaved by calpain activation, in the retina after intravitreal injection of NMDA. Intraperitoneal administration of ML233 increased the phosphorylation of Akt, a potent anti-apoptotic protein in neurons, in the retina. Furthermore, oral administration of ML233 protected against the decrease in the STR amplitudes and the loss of retinal ganglion cells caused by NMDA. These results suggest that systemic administration of ML233 protected retinal neurons from NMDA receptor-mediated excitotoxicity and that drugs activating the apelin receptor may be a new candidate for preventing the progression of these retinal diseases.
- Open Access
- 8 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-9
An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice
Pathological retinal angiogenesis is caused by the progression of ischemic retinal diseases and can result in retinal detachment and irreversible blindness. This neovascularization is initiated from the retinal veins and their associated capillaries and involves the overgrowth of vascular endothelial cells. Since expression of the apelin receptor (APJ) is restricted to the veins and proliferative endothelial cells during physiological retinal angiogenesis, in the present study, we investigated the effect of APJ inhibition on pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy (OIR). In vitro experiments revealed that ML221, an APJ antagonist, suppressed cultured-endothelial cell proliferation in a dose-dependent manner. Intraperitoneal administration of ML221 inhibited pathological angiogenesis but enhanced the recovery of normal vessels into the ischemic regions in the retina of the OIR model mice. ML221 did not affect the expression levels of vascular endothelial growth factor (VEGF) and its receptor (VEGFR2) in the retina. APJ was highly expressed in the endothelial cells within abnormal vessels but was only detected in small amounts in morphologically normal vessels. These results suggest that APJ inhibitors selectively prevent pathological retinal angiogenesis and that the drugs targeting APJ may be new a candidate for treating ischemic retinopathy.
- 8 November 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-9
Open AccessAn apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice
Pathological retinal angiogenesis is caused by the progression of ischemic retinal diseases and can result in retinal detachment and irreversible blindness. This neovascularization is initiated from the retinal veins and their associated capillaries and involves the overgrowth of vascular endothelial cells. Since expression of the apelin receptor (APJ) is restricted to the veins and proliferative endothelial cells during physiological retinal angiogenesis, in the present study, we investigated the effect of APJ inhibition on pathological retinal angiogenesis in a mouse model of oxygen-induced retinopathy (OIR). In vitro experiments revealed that ML221, an APJ antagonist, suppressed cultured-endothelial cell proliferation in a dose-dependent manner. Intraperitoneal administration of ML221 inhibited pathological angiogenesis but enhanced the recovery of normal vessels into the ischemic regions in the retina of the OIR model mice. ML221 did not affect the expression levels of vascular endothelial growth factor (VEGF) and its receptor (VEGFR2) in the retina. APJ was highly expressed in the endothelial cells within abnormal vessels but was only detected in small amounts in morphologically normal vessels. These results suggest that APJ inhibitors selectively prevent pathological retinal angiogenesis and that the drugs targeting APJ may be new a candidate for treating ischemic retinopathy.
- Open Access
- 1 January 2017
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 133 (1) , 34-41
Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
- 1 January 2017
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 133 (1) , 34-41
Open AccessApelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
- Open Access
- 1 January 2011
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 115 (2) , 239-243
Caspase-4 Directly Activates Caspase-9 in Endoplasmic Reticulum Stress–Induced Apoptosis in SH-SY5Y Cells
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2011
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 115 (2) , 239-243
Open AccessCaspase-4 Directly Activates Caspase-9 in Endoplasmic Reticulum Stress–Induced Apoptosis in SH-SY5Y Cells
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 November 2010
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (11) , 2182-2187
Apelin Is a Crucial Factor for Hypoxia-Induced Retinal Angiogenesis
Objective— To investigate the role of endogenous apelin in pathological retinal angiogenesis. Methods and Results— The progression of ischemic retinal diseases, such as diabetic retinopathy, is closely associated with pathological retinal angiogenesis, mainly induced by vascular endothelial growth factor (VEGF) and erythropoietin. Although antiangiogenic therapies using anti-VEGF drugs are effective in treating retinal neovascularization, they show a transient efficacy and cause general adverse effects. New therapeutic target molecules are needed to resolve these issues. It was recently demonstrated that the apelin/APJ system, a newly deorphanized G protein–coupled receptor system, is involved in physiological retinal vascularization. Retinal angiography and mRNA expression were examined during hypoxia-induced retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Compared with age-matched control mice, retinal apelin expression was dramatically increased during the hypoxic phase in oxygen-induced retinopathy model mice. APJ was colocalized in proliferative cells, which were probably endothelial cells of the ectopic vessels in the vitreous body. Apelin deficiency hardly induced hypoxia-induced retinal angiogenesis despite the upregulation of VEGF and erythropoietin mRNA in oxygen-induced retinopathy model mice. Apelin small and interfering RNA suppressed the proliferation of endothelial cells independent of the VEGF/VEGF receptor 2 signaling pathway. Conclusion— These results suggest that apelin is a prerequisite factor for hypoxia-induced retinal angiogenesis.
- 1 November 2010
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (11) , 2182-2187
Apelin Is a Crucial Factor for Hypoxia-Induced Retinal Angiogenesis
Objective— To investigate the role of endogenous apelin in pathological retinal angiogenesis. Methods and Results— The progression of ischemic retinal diseases, such as diabetic retinopathy, is closely associated with pathological retinal angiogenesis, mainly induced by vascular endothelial growth factor (VEGF) and erythropoietin. Although antiangiogenic therapies using anti-VEGF drugs are effective in treating retinal neovascularization, they show a transient efficacy and cause general adverse effects. New therapeutic target molecules are needed to resolve these issues. It was recently demonstrated that the apelin/APJ system, a newly deorphanized G protein–coupled receptor system, is involved in physiological retinal vascularization. Retinal angiography and mRNA expression were examined during hypoxia-induced retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Compared with age-matched control mice, retinal apelin expression was dramatically increased during the hypoxic phase in oxygen-induced retinopathy model mice. APJ was colocalized in proliferative cells, which were probably endothelial cells of the ectopic vessels in the vitreous body. Apelin deficiency hardly induced hypoxia-induced retinal angiogenesis despite the upregulation of VEGF and erythropoietin mRNA in oxygen-induced retinopathy model mice. Apelin small and interfering RNA suppressed the proliferation of endothelial cells independent of the VEGF/VEGF receptor 2 signaling pathway. Conclusion— These results suggest that apelin is a prerequisite factor for hypoxia-induced retinal angiogenesis.
- Open Access
- 1 January 2010
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 113 (2) , 153-160
Nitric Oxide Inhibits Lipopolysaccharide-Induced Inducible Nitric Oxide Synthase Expression and Its Own Production Through the cGMP Signaling Pathway in Murine Microglia BV-2 Cells
The present study examined the effect of the nitric oxide (NO) donor NOC18 on lipopolysaccharide (LPS)-induced NO production to investigate a regulation mechanism of NO production by microglial cells. LPS increased the levels of NO and inducible NO synthase (iNOS) protein in BV-2 murine microglial cells in a concentration-dependent manner. Pretreatment with NOC18 for 24 h concentration-dependently attenuated the LPS-induced iNOS protein expression and NO production. The inhibitory effect of NOC18 on LPS-induced NO production was partially blocked by LY83583, a soluble guanylate cyclase inhibitor. Pretreatment with dibutyryl guanosine-3′,5′-cyclic monophosphate (DBcGMP), a cell-permeable cGMP analogue, for 24 h attenuated partially LPS-induced iNOS protein expression and NO production. Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP. These results suggest that NO production by microglial cells is controlled by a negative feedback mechanism via the NO/cGMP signaling pathway.
- 1 January 2010
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 113 (2) , 153-160
Open AccessNitric Oxide Inhibits Lipopolysaccharide-Induced Inducible Nitric Oxide Synthase Expression and Its Own Production Through the cGMP Signaling Pathway in Murine Microglia BV-2 Cells
The present study examined the effect of the nitric oxide (NO) donor NOC18 on lipopolysaccharide (LPS)-induced NO production to investigate a regulation mechanism of NO production by microglial cells. LPS increased the levels of NO and inducible NO synthase (iNOS) protein in BV-2 murine microglial cells in a concentration-dependent manner. Pretreatment with NOC18 for 24 h concentration-dependently attenuated the LPS-induced iNOS protein expression and NO production. The inhibitory effect of NOC18 on LPS-induced NO production was partially blocked by LY83583, a soluble guanylate cyclase inhibitor. Pretreatment with dibutyryl guanosine-3′,5′-cyclic monophosphate (DBcGMP), a cell-permeable cGMP analogue, for 24 h attenuated partially LPS-induced iNOS protein expression and NO production. Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP. These results suggest that NO production by microglial cells is controlled by a negative feedback mechanism via the NO/cGMP signaling pathway.
- 1 May 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (1) , 28-34
Nitric oxide at a low concentration protects murine macrophage RAW264 cells against nitric oxide‐induced death via cGMP signaling pathway
We investigated the cytoprotective effect of low‐dose nitric oxide (NO) on NO‐induced cell death in mouse macrophage‐like cell line RAW264. Sodium nitroprusside (SNP), an NO donor, at a high concentration (4 mM) released cytochrome c from mitochondria and induced death in RAW264 cells. Acetyl‐L‐aspartyl‐L‐glutamyl‐L‐valyl‐L‐aspart‐1‐al (Ac‐DEVD‐CHO, 100–200 μM), a caspase‐3 inhibitor, attenuated the SNP‐induced cell death in a concentration‐dependent manner. Pretreatment with 100 μM SNP for 24 h, which had no effect on cell viability, attenuated the cell death and reduced cytochrome c release from mitochondria to the cytosol induced by 4 mM SNP. LY83583 (1–3 μM) and 1H‐[1,2,4]oxadiazolo[4,3,‐a]quinoxalin‐1‐one (ODQ, 30–100 μM), soluble guanylate cyclase inhibitors, negated the protective effect of the 100 μM SNP pretreatment. Pretreatment with 1 mM dibutylyl guanosine‐3′,5′‐cyclic monophosphate (DBcGMP), a cell‐permeable guanosine‐3′,5′‐cyclic monophosphate (cGMP) analogue, for 24 h inhibited both cytochrome c release and cell death induced by SNP. Protein kinase G inhibitor KT5823 (10 μM) significantly reduced the cytoprotective effects of low‐dose SNP and DBcGMP. These results indicate that low‐dose NO protects RAW264 cells from NO‐induced apoptosis through cGMP production and activation of protein kinase G. British Journal of Pharmacology (2003) 139, 28–34. doi:10.1038/sj.bjp.0705206
- 1 May 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (1) , 28-34
Nitric oxide at a low concentration protects murine macrophage RAW264 cells against nitric oxide‐induced death via cGMP signaling pathway
We investigated the cytoprotective effect of low‐dose nitric oxide (NO) on NO‐induced cell death in mouse macrophage‐like cell line RAW264. Sodium nitroprusside (SNP), an NO donor, at a high concentration (4 mM) released cytochrome c from mitochondria and induced death in RAW264 cells. Acetyl‐L‐aspartyl‐L‐glutamyl‐L‐valyl‐L‐aspart‐1‐al (Ac‐DEVD‐CHO, 100–200 μM), a caspase‐3 inhibitor, attenuated the SNP‐induced cell death in a concentration‐dependent manner. Pretreatment with 100 μM SNP for 24 h, which had no effect on cell viability, attenuated the cell death and reduced cytochrome c release from mitochondria to the cytosol induced by 4 mM SNP. LY83583 (1–3 μM) and 1H‐[1,2,4]oxadiazolo[4,3,‐a]quinoxalin‐1‐one (ODQ, 30–100 μM), soluble guanylate cyclase inhibitors, negated the protective effect of the 100 μM SNP pretreatment. Pretreatment with 1 mM dibutylyl guanosine‐3′,5′‐cyclic monophosphate (DBcGMP), a cell‐permeable guanosine‐3′,5′‐cyclic monophosphate (cGMP) analogue, for 24 h inhibited both cytochrome c release and cell death induced by SNP. Protein kinase G inhibitor KT5823 (10 μM) significantly reduced the cytoprotective effects of low‐dose SNP and DBcGMP. These results indicate that low‐dose NO protects RAW264 cells from NO‐induced apoptosis through cGMP production and activation of protein kinase G. British Journal of Pharmacology (2003) 139, 28–34. doi:10.1038/sj.bjp.0705206